WO2000016801A1 - Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques - Google Patents

Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques Download PDF

Info

Publication number
WO2000016801A1
WO2000016801A1 PCT/US1999/021991 US9921991W WO0016801A1 WO 2000016801 A1 WO2000016801 A1 WO 2000016801A1 US 9921991 W US9921991 W US 9921991W WO 0016801 A1 WO0016801 A1 WO 0016801A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
antibody
factor viii
cell
costimulatory
Prior art date
Application number
PCT/US1999/021991
Other languages
English (en)
Other versions
WO2000016801A9 (fr
Inventor
Jiahua Qian
Leon W. Hoyer
Mary Collins
Gary S. Gray
Original Assignee
Genetics Institute, Inc.
American Red Cross
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2000573762A priority Critical patent/JP2002526455A/ja
Priority to CA002343916A priority patent/CA2343916A1/fr
Priority to KR1020017003611A priority patent/KR20010085830A/ko
Priority to AU60578/99A priority patent/AU761206B2/en
Priority to EA200100385A priority patent/EA005236B1/ru
Priority to EP99969339A priority patent/EP1115423A1/fr
Priority to NZ511034A priority patent/NZ511034A/xx
Priority to IL14206999A priority patent/IL142069A0/xx
Application filed by Genetics Institute, Inc., American Red Cross filed Critical Genetics Institute, Inc.
Priority to HU0103960A priority patent/HUP0103960A3/hu
Priority to MXPA01002898A priority patent/MXPA01002898A/es
Priority to SI9920084A priority patent/SI20626A/sl
Priority to BR9913991-0A priority patent/BR9913991A/pt
Publication of WO2000016801A1 publication Critical patent/WO2000016801A1/fr
Publication of WO2000016801A9 publication Critical patent/WO2000016801A9/fr
Priority to NO20011412A priority patent/NO20011412L/no
Priority to LVP-01-62A priority patent/LV12768B/lv
Priority to HK02100157.7A priority patent/HK1039059A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des méthodes permettant de traiter des troubles hémostatiques au moyen d'agents stimulant l'hémostase et d'agents inhibant un signal costimulant dans un lymphocyte T. Les compositions et méthodes selon l'invention permettent de traiter les troubles hémostatiques au moyen de protéines thérapeutiques étrangères, tout en exerçant une modulation restrictive des réponses immunitaires à ces protéines thérapeutiques.
PCT/US1999/021991 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques WO2000016801A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
HU0103960A HUP0103960A3 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins
CA002343916A CA2343916A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques
MXPA01002898A MXPA01002898A (es) 1998-09-21 1999-09-21 Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
EA200100385A EA005236B1 (ru) 1998-09-21 1999-09-21 Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)
EP99969339A EP1115423A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques
NZ511034A NZ511034A (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins
IL14206999A IL142069A0 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins
JP2000573762A JP2002526455A (ja) 1998-09-21 1999-09-21 治療用たんぱく質に対する免疫応答を下方変調する方法
KR1020017003611A KR20010085830A (ko) 1998-09-21 1999-09-21 치료 단백질에 대한 면역 반응을 하향조절하는 방법
AU60578/99A AU761206B2 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins
SI9920084A SI20626A (sl) 1998-09-21 1999-09-21 Postopki za zaviralno moduliranje imunskega odziva na terapevtske proteine
BR9913991-0A BR9913991A (pt) 1998-09-21 1999-09-21 Métodos de sub-regulação da resposta imune a proteìnas terapêuticas
NO20011412A NO20011412L (no) 1998-09-21 2001-03-20 Fremgangsmåter for nedmodulering av immunresponsen til terapeutiske proteiner
LVP-01-62A LV12768B (lv) 1998-09-21 2001-04-20 Metode imūnās reakcijas nomākšanai pret terapeitiskām olbaltumvielām
HK02100157.7A HK1039059A1 (zh) 1998-09-21 2002-01-10 負調節對治療蛋白的免疫應答的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158,178 1998-09-21

Publications (2)

Publication Number Publication Date
WO2000016801A1 true WO2000016801A1 (fr) 2000-03-30
WO2000016801A9 WO2000016801A9 (fr) 2000-10-26

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021991 WO2000016801A1 (fr) 1998-09-21 1999-09-21 Methodes de modulation restrictive de la reponse immunitaire aux proteines therapeutiques

Country Status (21)

Country Link
EP (1) EP1115423A1 (fr)
JP (1) JP2002526455A (fr)
KR (1) KR20010085830A (fr)
CN (1) CN1331602A (fr)
AU (1) AU761206B2 (fr)
BR (1) BR9913991A (fr)
CA (1) CA2343916A1 (fr)
CZ (1) CZ20011021A3 (fr)
EA (1) EA005236B1 (fr)
HK (1) HK1039059A1 (fr)
HU (1) HUP0103960A3 (fr)
IL (1) IL142069A0 (fr)
LT (1) LT4920B (fr)
LV (1) LV12768B (fr)
MX (1) MXPA01002898A (fr)
NO (1) NO20011412L (fr)
NZ (1) NZ511034A (fr)
PL (1) PL346796A1 (fr)
SI (1) SI20626A (fr)
WO (1) WO2000016801A1 (fr)
ZA (1) ZA200103156B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
US6899879B2 (en) 1992-07-09 2005-05-31 Chiron Corporation Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies
US7040139B2 (en) * 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
US11246958B2 (en) 2015-05-11 2022-02-15 Haemostatix Limited Haemostatic compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005860A1 (fr) * 1994-08-19 1996-02-29 Novo Nordisk A/S Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
WO1996012406A1 (fr) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
WO1997034633A1 (fr) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
WO1998030241A1 (fr) * 1997-01-10 1998-07-16 Biogen, Inc. Procedes d'administration therapeutique de composes anti-cd40l
WO1998058672A1 (fr) * 1997-06-20 1998-12-30 Biogen, Inc. Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1993009804A1 (fr) 1991-11-18 1993-05-27 The Scripps Research Institute Polypeptides derives de la serine protease et anticorps anti-peptidiques, systemes et procedes therapeutiques empechant la coagulation du sang
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US8082673B2 (en) 2009-11-06 2011-12-27 Hexagon Metrology Ab Systems and methods for control and calibration of a CMM

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005860A1 (fr) * 1994-08-19 1996-02-29 Novo Nordisk A/S Methode de traitement d'un patient a l'aide d'un compose biologiquement actif
WO1996012406A1 (fr) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Therapie genique par administration concurrente et repetee d'adenovirus et d'agents immunodepresseurs
WO1997034633A1 (fr) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Procedes d'inhibition d'une reponse immune par blocage des voies de gp39/cd40 et ctla4/cd28/b7 et compositions utilisees avec ceux-ci
WO1998030241A1 (fr) * 1997-01-10 1998-07-16 Biogen, Inc. Procedes d'administration therapeutique de composes anti-cd40l
WO1998058672A1 (fr) * 1997-06-20 1998-12-30 Biogen, Inc. Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 92, no. 10, 15 November 1998 (1998-11-15), pages 709a, XP000867572 *
POTTER M.A. ET AL: "Suppression of immunological response against a transgene product delivered from micrencapsilated cells", HUMAN GENE THERAPY, vol. 9, 10 June 1998 (1998-06-10), pages 1275 - 1282, XP000867574 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899879B2 (en) 1992-07-09 2005-05-31 Chiron Corporation Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies
US7361345B2 (en) 1992-07-09 2008-04-22 Novartis Vaccines And Diagnostics, Inc. Anti-CD40 antibodies capable of blocking B-cell activation
US7790166B2 (en) 1992-07-09 2010-09-07 Novartis Vaccines And Diagnostics, Inc. Anti-CD40 antibodies capable of blocking B-cell activation
JP2003534291A (ja) * 2000-05-19 2003-11-18 ザ センター フォー ブラッド リサーチ インク Ｐ−セレクチン活性の変調による止血障害の診断及び治療方法
US7040139B2 (en) * 2003-06-10 2006-05-09 Smiths Detection Inc. Sensor arrangement
US11246958B2 (en) 2015-05-11 2022-02-15 Haemostatix Limited Haemostatic compositions

Also Published As

Publication number Publication date
KR20010085830A (ko) 2001-09-07
AU761206B2 (en) 2003-05-29
EA200100385A1 (ru) 2001-10-22
WO2000016801A9 (fr) 2000-10-26
NZ511034A (en) 2004-03-26
LV12768B (lv) 2002-06-20
NO20011412D0 (no) 2001-03-20
MXPA01002898A (es) 2002-06-04
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
HUP0103960A3 (en) 2003-09-29
PL346796A1 (en) 2002-02-25
NO20011412L (no) 2001-05-16
AU6057899A (en) 2000-04-10
LV12768A (en) 2001-12-20
LT4920B (lt) 2002-06-25
EP1115423A1 (fr) 2001-07-18
LT2001045A (en) 2002-01-25
HUP0103960A2 (hu) 2002-02-28
IL142069A0 (en) 2002-03-10
HK1039059A1 (zh) 2002-04-12
CN1331602A (zh) 2002-01-16
SI20626A (sl) 2002-02-28
ZA200103156B (en) 2002-07-18
EA005236B1 (ru) 2004-12-30
CA2343916A1 (fr) 2000-03-30
BR9913991A (pt) 2001-07-03

Similar Documents

Publication Publication Date Title
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
US20120269806A1 (en) Methods of inducing tolerance
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
EP0474691B1 (fr) Anticorps monoclonaux pour susciter une tolerance
Saenko et al. Haemophilia A: effects of inhibitory antibodies on factor VIII functional interactions and approaches to prevent their action
Miao et al. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
US20210355231A1 (en) Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
US20030161827A1 (en) Therapies that improve graft survival
US20010055593A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
Martín-Salces Hemophilia A: New Drugs
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
AU3437902A (en) Methods for modulating T cell unresponsiveness

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813510.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1/10, DRAWINGS, REPLACED BY A NEW PAGE 1/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 142069

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2343916

Country of ref document: CA

Ref document number: 2343916

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2001-1021

Country of ref document: CZ

Ref document number: PA/a/2001/002898

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 573762

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017003611

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 511034

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200103156

Country of ref document: ZA

Ref document number: 60578/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999969339

Country of ref document: EP

Ref document number: 9920084

Country of ref document: SI

Ref document number: 2001045

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: 200100385

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999969339

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017003611

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-1021

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001045

Country of ref document: LT

WWG Wipo information: grant in national office

Ref document number: 2001045

Country of ref document: LT

WWG Wipo information: grant in national office

Ref document number: 60578/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017003611

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-1021

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999969339

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001045

Country of ref document: LT